InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,652.00
(
0.06%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.59
(
0.00%
)
Bitcoin
60,800.01
(
0.01%
)
Post# of 2338742
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

imapro

Send PM Follow Ignore
Followers 100
Posts 2884
Boards Moderated 0
Alias Born 12/08/2012

imapro

Re: None

Monday, 01/22/2018 12:23:59 PM

Monday, January 22, 2018 12:23:59 PM

Post# of 2338742
VTGN NEWS
Jan 22, 2018 (Marketwired via COMTEX) -- SOUTH SAN FRANCISCO, CA--(Marketwired - January 22, 2018) - VistaGen Therapeutics Inc. VTGN, +5.18% a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, announced today that Shawn Singh, Chief Executive Officer of VistaGen, will provide an update on the Company's Phase 2 study of AV-101 as an oral new generation adjunctive treatment for Major Depressive Disorder (MDD) and outline key 2018 initiatives at the 14th Annual Noble Capital Markets' Investor Conference - NobleCon14 - to be held at the W Fort Lauderdale hotel in Fort Lauderdale, FL on Monday, January 29th at 4:30 p.m. ET.

The event will be available via video webcast on VistaGen's investor relations website, https://ir.vistagen.com/, the day following the live presentation.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up